Immunome (IMNM) Equity Average (2023 - 2025)
Historic Equity Average for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $266.6 million.
- Immunome's Equity Average rose 1374.84% to $266.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.6 million, marking a year-over-year increase of 1374.84%. This contributed to the annual value of $150.5 million for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Immunome's Equity Average is $266.6 million, which was up 1374.84% from $288.2 million recorded in Q2 2025.
- Immunome's 5-year Equity Average high stood at $288.2 million for Q2 2025, and its period low was $7.7 million during Q3 2023.
- Its 3-year average for Equity Average is $178.6 million, with a median of $218.5 million in 2024.
- In the last 5 years, Immunome's Equity Average soared by 294102.76% in 2024 and then skyrocketed by 685.68% in 2025.
- Quarter analysis of 3 years shows Immunome's Equity Average stood at $63.0 million in 2023, then surged by 214.45% to $198.0 million in 2024, then soared by 34.62% to $266.6 million in 2025.
- Its Equity Average stands at $266.6 million for Q3 2025, versus $288.2 million for Q2 2025 and $244.1 million for Q1 2025.